Early and accurate diagnosis is therefore of outmost importance and the presence of autoantibodies to citrullinated proteins/peptide (anti-CCP) has an important prognostic value for the disease.
These antibodies can be detected even before the onset of clinical symptoms. The anti-CCP2 test has a very high specificity and sensitivity and is a reliable and accurate toolset for the early diagnosis and follow-up of RA. Due to its wide clinical use, anti-CCP is included in the ACR/EULAR criteria for diagnosing RA.
Since the first report in 1998 that antibodies reacting with synthetic peptides containing the amino acid citrulline are highly specific for RA, the measurement of anti-CCP antibodies has become the method of choice in the accurate diagnosis of this disease.
The Svar CCP portfolio consists of enzyme-linked immunosorbent assay (ELISA) for detection and semi-quantitation of IgG antibodies to Cyclic Citrullinated Peptides (CCP) as well as rapid test for fast, near-patient diagnosis.
Over the years, we have teamed up with a range of partners; from small spin-outs to large diagnostic platform providers, to deliver quality assays for the benefit of patients worldwide. As an example, we have teamed up with some of the largest diagnostic platform companies in the world for out-licensing of our CCP2 assay, securing the availability of this innovation for more players, on more platforms, and ultimately for more patients. In these custom projects, we tailor a solution together with you to ensure the best fit, including options such as out-licensing and development support for specific platforms, OEM manufacturing performed by us under your label, or raw material and component supply. We ensure smooth development and adaptation to your platform through access to our highly experienced R&D team, and our skilled production engineers ensure high quality manufacturing to your specifications.